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Abstract
 
The T cell receptor must translate modest, quantitative differences in ligand binding kinetics
into the qualitatively distinct signals used to determine cell fate. Here, we use mice that express
an endogenous T cell receptor (TCR) antagonist and an adoptive transfer system to examine
the influence of TCR signal quality on the development of effector function. We show that
activation of antigen-specific T cells in the presence of an antagonist results in a functional re-
programming of the primary immune response, marked by altered T cell homing, a failure to
develop effector function, and ultimately clonal elimination by apoptosis. Importantly, antagonism
does not block cell division, implying that the signals promoting clonal expansion and effector
differentiation are distinct.
Key words: immune tolerance • clonal deletion • lymphocyte activation • immunization • 
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Introduction
 
Cell-autonomous instructional programs with sequentially
acquired activation thresholds control all phases of primary
and secondary T cell immune responses (1–5). For example,
sustained TCR cross-linking by high affinity MHC/foreign
peptide ligands on the surface of activated, professional
APCs results in clonal expansion, followed by differentiation
and effector function, clonal contraction, and ultimately
memory formation. In contrast, shorter interactions between
naive T cells and immature APCs presenting low doses of
antigen induce unresponsiveness and tolerance (3, 6, 7).
The outcome of T cell activation therefore depends largely
on the overall strength and duration of the initial antigenic
stimulation and the subsequent induction of the develop-
mental programs that control heritable changes in gene ex-
pression (1, 8). Collectively, the continuum of differentiation
stages after T cell stimulation characterizes the progressive
model of T cell activation (1, 4, 6, 9).
Multiple variables control signal strength and timing, and
therefore the capacity to induce full effector function.
These include the affinity and binding kinetics of the TCR
for cognate MHC/peptide ligands (10, 11), the presence or
absence of costimulatory molecules (12, 13), the cell surface
concentration of the relevant ligands/receptors (14, 15), the
nature of the APCs (16, 17), and competition for limited
niches in lymphatic tissue (18). These factors regulate the
rate of TCR triggering, signal amplification, and ultimately
the duration of the immunological synapse (19, 20). In the
progressive model of T cell differentiation, total signal
strength correlates with T cell “fitness,” or the capacity of
T cells to resist cell death, develop effector function, and
persist after primary stimulation in the absence of antigen
(2, 3). Mechanisms that interrupt the progressive nature of
this process are predicted to result in reduced survival capacity
and clonal elimination.
One potent mechanism capable of limiting synapse for-
mation and blocking T cell activation is TCR antagonism
(21–25). Antagonists are both naturally occurring and syn-
thetic ligands that fail to activate mature T cells (26–28).
When present together with a stimulatory ligand, antago-
nists will inhibit the expected proliferative response. Both
kinetic and membrane-proximal signaling mechanisms
have been proposed for this class of ligands, based largely on
data from in vitro experiments (10, 25, 29). Recently, TCR
antagonists have been shown to tip the kinase/phosphatase
balance at the CD3 complex in favor of recruitment of the
activated phosphatase SHP-1, resulting in negative feed-
back and T cell unresponsiveness (30, 31). These results
support the conclusion that TCR antagonists create a qual-
itatively distinct signal with a negative effect on T cell pro-
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liferation. The impact of this ubiquitous class of self-ligand
on the programming of peripheral T cell development is
largely unknown.
In previous work, we demonstrated that constitutive ex-
pression of a weak TCR antagonist ligand in vivo resulted
in a 2.5-fold decrease in the number of antigen-specific T
cells in the draining lymph nodes after adoptive transfer and
primary immunization (32). Although this study was the
first to demonstrate in vivo antagonism, its physiological sig-
nificance was limited by the inability to distinguish between
reduced proliferation and reduced survival as the mecha-
nism. Given the emerging positive role for self-ligands in T
cell activation (19, 33), it is important to determine if en-
dogenous peptide–MHC complexes also have the capacity
to negatively influence T cell programming and T cell sur-
vival, as predicted by studies of TCR antagonism that sup-
port a dominant negative signal model (34, 35).
We have examined this question by using a modification
of our previous adoptive transfer system together with mice
that constitutively express a strong TCR antagonist. Under
the conditions of these experiments, other factors that con-
tribute to the strength of TCR signaling are maximized and
normally lead to a robust Th1 cell response. Here, we show
that T cell activation in the presence of the antagonist results
in a functional reprogramming of the primary immune re-
sponse marked by clonal expansion, altered T cell homing, a
failure to develop effector function, and ultimately clonal
elimination by apoptosis. Although these data are consistent
with the progressive model of T cell differentiation (1), they
demonstrate the novel findings that the quality of T cell sig-
naling has a potent impact on T cell fate, and that the devel-
opmental programs promoting T effector function and clonal
expansion are distinct. They suggest a role for endogenous
TCR antagonists in establishing peripheral tolerance and shap-
ing the peripheral T cell repertoire.
 
Materials and Methods
 
Mice.
 
The generation and characterization of 3.L2 TCR
transgenic mice and I72 and A72 transgenic mice have been de-
scribed previously (36, 37). 3.L2 mice express a TCR specific for
Hb(64–76)/I-E
 
k
 
. I72 and A72 mice express a chimeric membrane
protein containing an altered peptide ligand of Hb(64–76) in all
APCs. In I72 mice, the normal asparagine at position 72 has been
replaced by isoleucine and in A72 mice it has been replaced by an
alanine. In hybridoma assays, these substitutions create peptides
that function as 3.L2 TCR antagonists by inhibiting IL-2 produc-
tion after in vitro stimulation (38). All experiments were per-
formed with 6–8-wk-old mice that were heterozygous for the
3.L2 TCR, I72, and A72 transgenes. All transgenic mice were
created in either the C57BL/6 or B6.AKR strain and maintained
on the B6.AKR background by backcrossing for 
 
 
 
30 generations.
Where possible, transgene
 
  
 
littermates were used as controls.
RAG-1
 
 
 
/
 
  
 
mice were maintained on the B6.AKR background as
described above. The Animal Resource Committee at the Medi-
cal College of Wisconsin approved all animal experiments.
 
Antibodies.
 
Antibodies and secondary reagents were pur-
chased from BD Biosciences and included the following: PE
anti–mouse CD4; FITC anti–mouse CD8a; biotin anti–mouse
CD19; purified anti–mouse CD16/CD32; biotin anti–mouse
TCR-
 
  
 
chain; biotin anti–mouse CD45R/B220; FITC anti–
mouse CD69; APC anti–mouse IL-2; APC anti–mouse IL-4;
APC anti–mouse IFN-
 
 
 
; APC anti–mouse TNF-
 
 
 
; and strepta-
vidin-CyChrome. Biotinylated 3.L2 clonotypic antibody (CAb)
was prepared as described previously (36).
 
Peptides.
 
The Hb(64–76), Hb(64–76)N72I (I72), and MCC
(88–103) peptides were purified by HPLC and analyzed by mass
spectroscopy (United Biochemical Research). The peptide se-
quences in single letter amino acid code are as follows: GKKVI-
TAFNEGLK (Hb); GKKVITAFIEGLK (I72); and ANERADL-
IAYLKQATK (MCC).
 
Ex Vivo Antagonism Assay.
 
B6.AKR splenocytes were prepulsed
with 10 
 
 
 
M Hb(64–76) peptide for 3 h at 37
 
 
 
C, 5% CO
 
2
 
, and
washed three times to remove unbound peptide. CD4
 
  
 
T cells
were purified from the spleens of 3.L2 mice by magnetic sorting
with anti-CD4 beads using the conditions specified by the manu-
facturer (Miltenyi Biotec), and the percent of CAb
 
  
 
cells was de-
termined by FACS. 5 
 
  
 
10
 
5 
 
prepulsed, washed splenocytes were
added to 2.5 
 
  
 
10
 
4 
 
CAb
 
  
 
cells in a 96-well plate, followed by ti-
trated amounts of I72 or MCC(88–103) peptide. All cells and
peptides were resuspended in cell culture media (RPMI 1640,
10% FBS, 5 
 
  
 
10
 
 
 
5 
 
M 2-ME, and 1 mM glutamax), and tripli-
cate wells were set up for each peptide concentration. Cultures
were incubated for 48 h at 37
 
 
 
C, 5% CO
 
2
 
, pulsed with 0.4 
 
 
 
Ci/
well [
 
3
 
H]thymidine for an additional 18 h, and then harvested
onto fiber filtermats with a Micro96 harvester (Skatron) and
counted.
 
T Cell Proliferation Assays.
 
CD4
 
  
 
T cells were isolated from
3.L2 mice by magnetic bead sorting and the percentage of CAb
 
 
 
cells was determined by FACS. 2.5 
 
  
 
10
 
4 
 
CD4
 
  
 
CAb
 
  
 
T cells
were added to 5 
 
  
 
10
 
5 
 
splenocytes, and the T cells were stimu-
lated with either Hb(64–76) or the I72 peptide as described previ-
ously (39). Results from several experiments were then averaged
to obtain the data shown. In some experiments, the source of
APCs was either I72 transgenic or B6.AKR (control) splenocytes.
For the hybridoma assay, 5 
 
  
 
10
 
5 
 
splenocytes from either I72 or
B6.AKR mice were used as APCs to present the MCC(88–103)
peptide to 2.5 
 
  
 
10
 
4 
 
2B4 hybridoma cells in triplicate wells. The
2B4 hybridoma is specific for MCC(88–103)/I-E
 
k
 
. After 24 h,
100 
 
 
 
l of culture supernatant was removed and the relative
amount of IL-2 in the supernatant was determined using the IL-
2–dependent cell line CTLL-2 as described previously (39).
 
Adoptive Transfer and Immunization.
 
Pooled donor spleno-
cytes were isolated from 3.L2 or 3.L2 
 
  
 
RAG
 
 
 
/
 
  
 
TCR trans-
genic mice and filtered. The percent of CD4
 
  
 
CAb
 
  
 
T cells in
the suspension was determined by FACS, and 10
 
6 
 
CD4
 
  
 
CAb
 
 
 
cells were transferred intravenously into recipient mice by retro-
orbital injection. After 24 h, transfer recipients were immunized
subcutaneously with 2 or 20 nmol of Hb(64–76) peptide emulsi-
fied in CFA (100 
 
 
 
l per mouse). At various times after immuni-
zation, the draining lymph nodes and spleen were removed and
analyzed by cell count and FACS.
 
5-(and -6)-Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE)
Staining.
 
Splenocytes were labeled with the intracellular fluores-
cent CFSE (Molecular Probes) before transfer. A single cell sus-
pension containing 50 
 
  
 
10
 
6 
 
cells/ml in Dulbecco’s PBS and
5
 
 
 
M CFSE was incubated at 37
 
 
 
C for 15 min. After this incuba-
tion, the cells were washed three times with ice-cold DPBS, fil-
tered, and resuspended at a concentration of 20 
 
  
 
10
 
6 
 
CD4
 
 
 
CAb
 
  
 
cells/ml. Each transfer recipient received 5 
 
  
 
10
 
6 
 
CD4
 
 
 
CAb
 
  
 
cells (250 
 
 
 
L). Controls included recipients that were ei-
ther not immunized or immunized with CFA alone. 
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Flow Cytometry.
 
Single cell suspensions of lymph node cells
or splenocytes were stained as described previously (37). Samples
were gated on live cells and a minimum of 100,000 live cell
events per sample were collected.
 
Immunohistochemistry.
 
Popliteal lymph nodes were removed
and sectioned as described previously (37). The sections were in-
cubated with the primary antibody, a biotinylated anti–mouse
CD45R/B220 (0.5 
 
 
 
g in 100 
 
 
 
L FACS buffer), for 1 h. Sections
were washed four times with FACS buffer and incubated with
Cy
 
 
 
3–conjugated streptavidin (Jackson ImmunoResearch Labora-
tories) for 30 min (1.8 
 
 
 
g streptavidin in 50 
 
 
 
L FACS buffer).
Slides were then washed three times in FACS buffer and a 50%
glycerol/PBS solution was applied, followed by a sealed cover-
slip. Immunofluorescence was visualized on an Olympus BX60
microscope. Digital images were captured by an Axio Vision 3.0
Carl Zeiss vision imaging system and processed using Adobe
Photoshop and Deneba Canvas software.
 
Intracellular Cytokine Analysis.
 
CD4
 
  
 
T cells were purified
from the spleens and lymph nodes of day 5 transfer recipients.
The percent of CAb
 
  
 
lymphocytes was determined by FACS and
2.5 
 
  
 
10
 
4 
 
CAb
 
  
 
cells were added to 4.75 
 
  
 
10
 
5 
 
B6.AKR spleno-
cytes in a 96-well plate. The splenocytes were prepulsed with 10
 
 
 
M Hb(64–76) peptide for 3 h at 37
 
 
 
C before the addition of the
purified T cells. After the addition of the CAb
 
  
 
cells, the culture
was incubated at 37
 
 
 
C, 5% CO
 
2
 
, for 24 h. Brefeldin A was then
added at a final concentration of 10 
 
 
 
g/ml and cells were incu-
bated for an additional 12 h before analysis. Surface staining of
cells was performed before intracellular staining using a modified
FACS buffer containing 5 
 
 
 
g/ml brefeldin A. Cells were stained
on ice for 30 min with the primary antibody, washed with the
modified FACS buffer, and incubated for 20 min on ice with the
streptavidin-conjugated fluorochrome. Cells were washed again
with the modified FACS buffer and prepared for intracellular cy-
tokine staining by adding 200 
 
 
 
l of a fixation and permeabiliza-
tion solution (FACS buffer with 2% paraformaldehyde and 0.1%
saponin), followed by a 20-min incubation at room temperature.
After this incubation, permeabilization was continued by adding
3 ml of permeabilization wash (FACS buffer with 0.1% saponin)
for 10 min at room temperature. Cells were collected by centrif-
ugation and stained for IL-2, IL-4, IFN-
 
 
 
, and TNF-
 
  
 
by adding
APC-conjugated antibodies at 0.2 
 
 
 
g/ml in 100 
 
 
 
l of permeabi-
lization wash for 1 h on ice. Unrelated antibodies of the same iso-
types were used as controls. Cells were then washed in normal
FACS buffer (without saponin) and then fixed with 1% parafor-
maldehyde in PBS-azide (0.1%). Cells were immediately sub-
jected to FACS analysis.
 
Hb(64–76) Recall Responses.
 
Adoptive transfer recipients were
immunized with 2 nmol Hb(64–76) peptide in CFA as described
above. The mice were reimmunized 2 mo later with 20 nmol
Hb(64–76) in IFA. 5 d after the secondary immunization, the
draining lymph nodes and spleen were removed and single cell
suspensions were prepared. An aliquot of this suspension was ana-
lyzed using flow cytometry. CD4
 
  
 
T cells were isolated from
these suspensions using anti-CD4 microbeads and Fc block (5 
 
 
 
g
for 10
 
7 
 
cells). Proliferation assays were performed in triplicate in
96-well flat-bottom plates using 3.5 
 
  
 
10
 
5 
 
purified CD4
 
  
 
T cells,
6.5 
 
  
 
10
 
5 
 
B6.AKR splenocytes, and varying concentrations of
Hb(64–76) peptide per well. After incubation for 48 h, cells were
pulsed with 0.4 
 
 
 
Ci/well [
 
3
 
H]thymidine and harvested 24 h later.
 
Online Supplemental Material.
 
Adoptively transferred 3.L2 T
cells isolated from RAG-1
 
 
 
/
 
  
 
donors proliferate equally in I72
 
 
 
and I72
 
  
 
recipients 48 h after immunization with Hb(64–76)
peptide (Fig. S1). Adoptively transferred 3.L2 T cells proliferate
at equal rates in A72
 
  
 
recipients after immunization (Fig. S2).
Figs. S1 and S2 are available at http://www.jem.org/cgi/content/
full/jem.20041226/DC1.
 
Results
 
Naive T Cells Are Susceptible to Antagonism.
 
The I72
peptide is a strong antagonist for the 3.L2 T cell hybrid-
oma, and we wished to establish that this peptide would
also antagonize the proliferation of 3.L2 transgenic T cells
(38). In this ex vivo antagonism assay, B6.AKR splenocytes
were prepulsed with Hb(64–76) and used as APCs. When
naive, freshly isolated 3.L2 transgenic T cells were added to
the culture wells, they were activated and proliferated, as
measured by [
 
3
 
H]thymidine incorporation. These condi-
tions result in 
 
 
 
17,000 cpm (Fig. 1 A). When increasing
concentrations of I72 peptide were added, the 3.L2 re-
sponse is reduced by 
 
 
 
75% at 100 
 
 
 
M. These results dem-
onstrate that naive transgenic 3.L2 T cells are susceptible to
antagonism by the I72 peptide. The control peptide
MCC(88–103), which also binds to I-E
 
k
 
, failed to inhibit
Figure 1. The antagonist I72 inhibits the proliferation of naive 3.L2 T
cells. (A) Ex vivo antagonism assay with purified naive 3.L2 T cells, sple-
nocytes prepulsed with 10  M Hb(64–76) peptide as APCs and no addi-
tional peptide (dotted line), increasing concentrations of the antagonist I72
peptide ( ), or the MCC(88–103) control peptide ( ). Data shown is the
mean cpm from 12 independent experiments. (B) Proliferation assay with
purified naive 3.L2 T cells and splenocytes as APCs, with increasing con-
centrations of Hb(64–76) ( ) or I72 peptide ( ). Data shown is the mean
of seven experiments. (C) Proliferation assay with purified naive 3.L2 T
cells stimulated by Hb(64–76) peptide and control splenocytes ( ), or
splenocytes from transgenic mice expressing the antagonist I72 in all MHC
class II  cells ( ). Data shown is the mean of three experiments. (D) Hy-
bridoma assay with the 2B4 T cell hybridoma, increasing concentrations of
the MCC(88–103) peptide, and either control splenocytes ( ) or I72 sple-
nocytes as APCs ( ). Data shown is the mean of two experiments.TCR Antagonists Promote Tolerance by Clonal Elimination 1374
3.L2 T cell proliferation, demonstrating the specificity of
this inhibition. In ex vivo proliferation assays, the I72 pep-
tide did not induce 3.L2 T cell proliferation (Fig. 1 B).
The transgenic mouse line I72 expresses a chimeric
membrane protein containing the I72 peptide as an epitope
tag in all MHC class II  cells (37). Previous data demon-
strated the efficient processing and presentation of the I72
epitope in all APCs, including B cells and in the thymus.
I72 mice express sufficient ligand to induce negative selec-
tion of 3.L2 transgenic T cells. Because the strength of the
antagonism effect correlates with the concentration of I72
(Fig. 1 A), we wished to determine if APCs derived from
I72 mice would also inhibit the naive 3.L2 T cell response.
In this ex vivo assay, purified CD4  3.L2 T cells were
mixed with either I72  (transgenic) or I72  (B6.AKR)
splenocytes in the presence of increasing concentrations of
the Hb(64–76) peptide. Results show a 7–10-fold shift in
the dose response curve at all peptide concentrations (Fig. 1
C), demonstrating that the antagonist effect produced by
I72 splenocytes cannot be overcome at high doses of ago-
nist peptide. In Fig. 1, a comparison of A with C demon-
strates that the level of inhibition of proliferation achieved
by I72  splenocytes is, on average, equal to that achieved
by the addition of 31.6–100  M I72 peptide in the antago-
nism assay (50–75%).
Importantly, both I72 and B6.AKR splenocytes are
equivalent in their ability to present MCC(88–103), an un-
related peptide that also binds to I-Ek and is recognized by
the 2B4 hybridoma (Fig. 1 D). These data demonstrate that
the inhibition seen in Fig. 1 C is not due to fewer available
I-Ek binding sites, and led us to further examine the ability
of I72 mice to inhibit both primary and secondary 3.L2 im-
mune responses to Hb(64–76).
Antagonism Does Not Inhibit Clonal Expansion. The ef-
fect of the I72 ligand on 3.L2 proliferation shortly after im-
munization was examined by labeling 3.L2 T cells with
CFSE before adoptive transfer (5   106 cells). I72  and I72 
transfer recipients were immunized subcutaneously with 2
nmol Hb(64–76) 1 d after transfer. 2 d after immunization,
the draining lymph nodes and spleen were examined by
flow cytometry for 3.L2 T cell proliferation, as measured by
the interval decreases in CFSE fluorescence. Both I72  and
I72  mice show proliferation of 3.L2 T cells in the lymph
nodes and the spleen (Fig. 2, A and B, panels 3, 6, 9, and
12), and the kinetics of this early expansion are equivalent.
In the absence of immunization, no proliferation of 3.L2 T
cells is seen in the lymph nodes of either I72  or I72  mice
(Fig. 2, A and B, panels 1 and 4), demonstrating that the in-
teraction of 3.L2 T cells with I72 in vivo does not result in
T cell activation. 3.L2 T cells in the spleen also show no
turnover in the absence of antigen-specific activation (Fig.
2, A and B, panels 7 and 10). When mice were immunized
with CFA alone, no 3.L2 proliferation was observed in ei-
ther the lymph node or spleen (Fig. 2, A and B, panels 2, 5,
8, and 11). Taken together, these results show that the pres-
ence of I72 does not inhibit 3.L2 T cells from entering cell
cycle after immunization with Hb(64–76) peptide. A reduc-
Figure 2. Adoptively transferred naive 3.L2 T cells expand equally in
both I72  and I72  mice after immunization with Hb(64–76) peptide.
CFSE-labeled whole splenocytes containing 5   106 CAb  cells were
transferred intravenously into I72  or I72  mice and immunized as indi-
cated. The draining lymph nodes and spleens were harvested 48 h after
immunization and analyzed by FACS. (A) Dot plot analysis of the CD4 
population for expression of the 3.L2 TCR and CFSE content. (B) His-
togram analysis of the CD4  CAb  gate shown in A. This experiment is
representative of seven similar experiments.Haribhai et al. 1375
tion in the proliferative response was certainly expected
from the ex vivo antagonism data and the current models of
peripheral T cell differentiation.
The CFSE data demonstrate that the interaction be-
tween 3.L2 T cells and the I72 ligand in the absence of im-
munization with Hb(64–76) does not result in cell division.
These results also show that CFA-induced activation of
APCs in the draining lymph nodes of I72 mice is not suffi-
cient for 3.L2 T cell stimulation and does not result in 3.L2
bystander activation. Finally, 3.L2 T cells purified from
unimmunized I72  and I72  transfer recipients respond
equally to ex vivo stimulation with Hb(64–76) peptide,
suggesting that exposure to the endogenous antagonist I72
alone does not permanently alter TCR signaling (unpub-
lished data).
In many TCR transgenic models, including 3.L2 mice,
the transgenic   chain may pair with an endogenously rear-
ranged   chain, generating a second TCR of unknown
specificity. Although the data in Fig. 2 shows that all prolif-
eration occurs in the CD4  CAb  population, we ruled out
any potential contribution of a second TCR by repeating
the experiment with 3.L2 T cells isolated from 3.L2  
RAG-1 /  mice. These data also show equal prolifera-
tion in both I72  and I72  mice, confirming the results
obtained with the transfer of whole splenocytes (Fig. S1,
which is available at http://www.jem.org/cgi/content/
full/jem.20041226/DC1).
When comparing lymph node with splenocyte CFSE
staining, a greater number of divided 3.L2 T cells is ob-
served in the spleens of both I72  and I72  mice (Fig. 2, A
and B, panels 9 and 12). The site of the initial activation of
these cells is uncertain. After subcutaneous immunization,
antigen-loaded, activated dendritic cells migrate to the
draining lymph nodes, where the first T cell–APC interac-
tions occur (17). However, by 48 h after immunization, it
is also apparent that 3.L2 T cell division is initiated in the
spleen. In our experiments, we cannot directly determine
the number of 3.L2 T cell divisions that occur within the
Figure 3. Antagonism results in a redistribution of acti-
vated 3.L2 T cells. (A) Whole splenocytes containing 106
CAb  cells were transferred intravenously into I72  ( )
and I72  ( ) mice and immunized as described in Materi-
als and Methods. The draining lymph nodes and spleens
were removed 2–10 d after immunization. Lymph nodes
were pooled and the total number of CD4  CAb  T cells
per lymph node and spleen was determined by cell counting
and FACS. Multiple experiments were averaged to obtain
each data point, and the total number of mice used is as
follows: day 2 (7 I72 , 6 I72 ), day 3 (6 I72 , 5 I72 ), day
4 (10 I72 , 9 I72 ), day 5 (19 I72 , 16 I72 ), day 7 (9
I72 , 9 I72 ), and day 10 (6 I72 , 6 I72 ). Error bars rep-
resent standard error of the mean. (B) Dual receptor T cells
have no effect on the 3.L2 T cell proliferative response. A
comparison of the number of 3.L2 T cells found in the
lymph nodes and spleens of I72  and I72  mice on day 5
after immunization using whole 3.L2 splenocytes (open
bars) and splenocytes from 3.L2   RAG-1 /  mice (closed
bars). Only those experiments in which all four draining
lymph nodes were available were used to generate this
data, and the number of mice in each group is indicated.
(C) There is no effect of antigen dose on the 3.L2 re-
sponse. Transfer recipients were immunized with either 2
(light gray bars) or 20 nmol (dark gray bars) of Hb(64–76)
peptide. The day 5 responses are shown, and the number
of mice in each group is indicated.TCR Antagonists Promote Tolerance by Clonal Elimination 1376
spleen or the number of 3.L2 T cells that were first stimu-
lated in this lymphoid organ.
Altered Homing Properties of Antagonized T Cells. Adop-
tive transfer and immunization were used to examine the
primary 3.L2 immune response in the presence of the antag-
onist I72. In these experiments, whole splenocytes contain-
ing 106 unlabeled 3.L2 T cells were transferred intrave-
nously, and the mice were immunized with two nmol
Hb(64–76) in CFA 24 h later. Four-color analytical flow cy-
tometry was used to examine the draining lymph nodes and
spleen for cell surface expression of CD4, CD8, CD19, and
the 3.L2 TCR at multiple time points after immunization.
A robust expansion of 3.L2 T cells is seen in the draining
lymph nodes of I72  mice, with 2.8   106 3.L2 T cells per
lymph node seen on day 5 after immunization (Fig. 3 A).
Mice expressing the endogenous antagonist I72  have a sev-
enfold reduction in 3.L2 T cell numbers at this same time
point, with  0.4   106 3.L2 T cells per lymph node. The
kinetics of T cell expansion are similar. The antigen-specific
3.L2 T cell response peaks in the lymph nodes on day 5 in
both I72  and I72  mice. 10 d after immunization, there are
0.5   106 3.L2 T cells per lymph node in I72  controls,
whereas 3.L2 T cells in I72  mice are barely detectable.
Analysis of splenocytes shows a reversal of this effect,
with preferential accumulation of 3.L2 T cells in I72 
spleens. In the I72  mice, there are 16   106 3.L2 T cells
per spleen at the peak response on day 5 (Fig. 3). In con-
trast, there are only 6   106 3.L2 T cells per spleen in I72 
mice on day 5. This represents an  2.5-fold increase in the
number of 3.L2 T cells in the spleens of I72  mice at the
peak of expansion. The numbers have equalized by day 10,
when both I72  and I72  mice have 4   106 3.L2 T cells
per spleen. Importantly, the total number of T cells isolated
from the four draining lymph nodes and spleen of I72  and
I72  mice at the peak of clonal expansion are nearly equiv-
alent (Fig. 3 B; I72    18.0   106/mouse and I72   
18.3   106/mouse). This suggests that the magnitude of
the proliferative response in both groups is the same.
A similar alteration in lymphocyte distribution was seen
in adoptive transfer experiments performed with 3.L2 T
cells isolated from 3.L2   RAG /  mice (Fig. 3 B) and
with purified 3.L2 T cells (unpublished data). Also, results
were the same when mice were immunized with 20 nmol
Hb(64–76) peptide, rather than 2 nmol (Fig. 3 C). These
control experiments demonstrate that neither the transfer
of whole splenocytes or the dose of immunizing peptide
influenced the results.
Furthermore, these results are consistent with our previ-
ous studies using 3.L2 T cells and mice expressing the weak
antagonist A72 (32, 39). In these earlier studies, we ob-
served a 2.5-fold decrease in the number of 3.L2 T cells in
the draining lymph nodes, reflecting the weaker antago-
nism. The number of 3.L2 T cells in the spleen was not ex-
amined and we could not distinguish between reduced
proliferation and reduced survival. Based on the data pre-
sented here, we labeled 3.L2 T cells with CFSE and per-
formed adoptive transfer studies with mice expressing the
A72 ligand as described in Fig. 2. Results confirm that after
Figure 4. T cell antagonism limits B cell expan-
sion and secondary follicle formation. (A) From
the experiments shown in Fig. 3, the total
number of CD19  cells per lymph node and
spleen was also determined. (B) The location of
B cells in draining lymph nodes was examined
by immunohistochemistry. Frozen sections
were stained with anti-B220 and visualized as
described in Materials and Methods. The peak
of B cell expansion and of secondary B cell follicle
formation occurs 7 d after immunization and is
absent in I72  mice. No statistically significant
difference in the number of splenic B cells was
observed.Haribhai et al. 1377
immunization with Hb(64–76) peptide, 3.L2 T cells in
the draining lymph nodes and spleen divide at the same
rate in both A72  and I72  mice, as expected (Fig. S2,
which is available at http://www.jem.org/cgi/content/
full/jem.20041226/DC1, and Fig. 2).
After adoptive transfer of 3.L2 T cells and immunization
with Hb(64–76) peptide, B cell expansion is also seen in
the draining lymph nodes of I72  and I72  mice (Fig. 4 A).
However, at the peak of the B cell response on day 7, there
is a threefold decrease in the number of B cells in I72  mice
relative to I72  controls. These data suggest that activation
of 3.L2 T cells in the presence of the I72 ligand results in
poor or limited B cell help. Frozen sections of draining
lymph nodes from I72  and I72  stained for B cells confirm
a decrease in secondary follicle formation on day 7 in I72 
mice (Fig. 4 B). There is a modest expansion of B cells in
the spleens of I72  and I72  mice, with no statistically sig-
nificant difference between the two groups (Fig. 4 A; day
7, P   0.23). It is important to note that the accelerated B
cell response in the lymph nodes of I72  transfer recipients
is due to the high precursor frequency of 3.L2 T cells. In
normal mice (no transfer), the peak B cell response and the
peak of secondary B cell follicle formation occur approxi-
mately 10 d after immunization and are the result of the re-
sponse to CFA (unpublished data). It is therefore possible
to distinguish the component of B cell expansion driven by
activated 3.L2 T cells from that occurring in response to
the adjuvant.
Antagonized T Cells Are Anergic. The abortive immune
response occurring in the draining lymph nodes of I72 
mice, marked by the large decrease in 3.L2 T cell numbers,
suggested that the expanded population of 3.L2 T cells
found in the spleens was nonfunctional. To evaluate this
possibility, we purified CD4  T cells from the lymph nodes
and spleens of I72  and I72  mice on day 5 after immuni-
zation. FACS was used to determine the number of 3.L2 T
cells in each sample and 2.5   104 3.L2 T cells were mixed
with 4.75   105 B6.AKR splenocytes per well in a 96-well
plate. These cells were restimulated with 10  M Hb(64–
76) peptide for 18, 24, and 36 h, and were examined by
FACS for the expression of CD69 and the intracellular cy-
tokines IL-2, TNF- , IFN- , and IL-4. The data in Fig. 5,
A and B, are from one of three representative experiments
analyzed at the time point that gives maximal cytokine ex-
pression (IL-2 18 h, all others 36 h). These data show that
3.L2 T cells isolated from the lymph nodes and spleens of
I72  mice are unable to make IL-2, IFN- , and TNF-  af-
ter restimulation ex vivo. This is in contrast to 3.L2 T cells
isolated from the lymph nodes and spleens of I72  controls,
which respond with a burst of IL-2, IFN- , and TNF- 
production. The anergic 3.L2 T cells do up-regulate
CD69, although at reduced levels compared with controls
(Fig. 5 B). No T cells from these experiments produce IL-4
due to the strong Th1 cell bias created by immunizing with
CFA (unpublished data). Together, these data demonstrate
that 3.L2 T cells stimulated in the presence of the antago-
Figure 5. 3.L2 T cells increase
CD69 expression, but fail to de-
velop effector function in the
presence of the antagonist I72.
CD4  3.L2 T cells were purified
from the draining lymph nodes
and spleens of I72  and I72  mice
on day 5 after immunization.
Equal numbers of 3.L2 T cells
were restimulated in culture with
B6.AKR splenocytes prepulsed
with Hb(64–76) peptide. After
24 h, the cells were removed and
stained for cell surface markers
and intracellular cytokines as de-
scribed in Materials and Methods.
Quadrants were established using
isotype-matched control antibod-
ies. (A) CD4  cells were analyzed
for the expression of the 3.L2
TCR and IL-2, IFN- , or TNF- .
No cytokine expression is seen
in 3.L2 T cells isolated from I72 
mice. (B) CD4  CAb  cells were
analyzed for the cell surface ex-
pression of CD69 and intracellu-
lar cytokines as described above.
Many 3.L2 T cells isolated from
I72   mice have up-regulated
CD69, yet fail to develop effector
function. The data shown is rep-
resentative of three experiments.TCR Antagonists Promote Tolerance by Clonal Elimination 1378
nist I72 fail to achieve full activation, resulting in antigen-
specific clonal anergy.
Antagonism Results in Activation of Caspase-3. As shown
above, 3.L2 T cells in immunized I72  mice fail to acquire
an effector phenotype. This lack of effector function to-
gether with the rapid loss of 3.L2 T cells from the spleens
of I72  mice seen by day 10 suggested that the proliferative
program activated in these cells ultimately resulted in apop-
tosis. FACS experiments failed to show up-regulation of
FasL or Fas on 3.L2 T cells from I72  mice, making activa-
tion-induced cell death unlikely (unpublished data). Fur-
ther examination by intracellular staining revealed activated
caspase-3 in  30% of 3.L2 T cells from the spleens of I72 
mice. Activated caspase-3 was seen in only 1% of 3.L2 T
cells isolated from I72  controls (Fig. 6). One plausible ex-
planation, based on the lack of IL-2 production and the ac-
tivation of caspase-3, is that the antagonized 3.L2 T cells
fail to survive due to lack of a survival signal, leading to un-
opposed apoptotic cell death.
T Cell Memory Is Aborted. The loss of 3.L2 T cells from
I72  mice after immunization with Hb(64–76) peptide was
rapid but not complete 10 d after primary immunization
(Fig. 3). Given the altered distribution and lack of effector
function seen in activated 3.L2 T cells in I72  mice, it was
possible that the development of 3.L2 T cell memory would
also be affected. To test this hypothesis, I72  and I72  litter-
mate control mice were transferred and immunized as de-
scribed in the experiments for Fig. 3. After 3, 4, 6, and 10
wk, the draining lymph nodes and spleen were removed
and analyzed for the presence of 3.L2 T cells by FACS. The
results show that 3.L2 T cells are clearly detectable in the
lymph nodes of I72  mice at all time points, whereas no
3.L2 T cells are seen in the lymph nodes of I72  mice at any
time point. However, in the spleens of both I72  and I72 
mice, 3.L2 T cells can be visualized for 6 wk after primary
immunization at approximately equal numbers (Fig. 7 A).
In the absence of the antagonist, clonotype  CD44hi cells
could be detected in the spleens (5.6   103 cells/spleen) and
lymph nodes (3.7   103 cells/lymph node) of I72  mice 10
wk after primary immunization (Fig. 7 B), consistent with
the formation of 3.L2 T cell memory.
This inability to detect 3.L2 T cells in I72  mice by 6–8
wk after primary immunization was consistent with the hy-
pothesis that the antagonism affects the development of T
cell memory. To further evaluate this possibility, adoptive
transfer recipients were reimmunized subcutaneously with
20 nmol Hb(64–76) peptide in IFA 10 wk after the primary
immunization. 5 d later, the draining lymph nodes and
spleen were removed. Cells were analyzed for surface ex-
pression of CD4, CD8, and the 3.L2 TCR (Fig. 7 A, far
right panels). In I72  mice, the number of CD4  CAb 
cells in both lymph nodes and spleen did not exceed that
seen with the isotype control antibody (isotype control val-
ues: 0.4   106 cells/spleen and 0.065   106 cells/lymph
nodes; unpublished data), also suggesting a lack of 3.L2 T
cell memory in these mice.
The suspected influence of the endogenous antagonist
I72 on the formation of 3.L2 T cell memory was con-
firmed by proliferation assay. After secondary immuniza-
tion, the CD4  T cell population from lymph nodes and
spleens was isolated by magnetic bead cell sorting to re-
move APCs containing I-Ek–Hb(64–76) or I-Ek–I72 com-
plexes. Purified CD4  T cells were then added to B6.AKR
splenocytes in culture and stimulated with Hb(64–76) pep-
tide. Results show a proliferative response to Hb(64–76)
peptide in T cells isolated from I72  controls, but virtually
no T cell response in the cells isolated from I72  mice (Fig.
7 C). The small response seen in normal I72  mice (no
adoptive 3.L2 transfer) immunized with Hb(64–76) peptide
reflects the response of the endogenous T cell repertoire to
immunization and boosting with Hb(64–76) peptide. In
contrast, the proliferative response of I72  transfer recipi-
ents and I72  controls is approximately equal and barely
detectable. This reduced reactivity might be due to nega-
tive selection of the Hb(64–76)-reactive repertoire in the
thymus of I72  mice. Taken together, these data demon-
strate that activation of 3.L2 T cells in the presence of the
endogenous antagonist I72 results in an abrogation of 3.L2
T cell memory.
Discussion
In this paper, we have used an adoptive transfer model to
examine the effect of a TCR antagonist on an antigen-spe-
cific immune response. We find that activation of trans-
ferred CD4  transgenic T cells in the presence of an en-
dogenously expressed antagonist results in antigen-specific
clonal expansion while altering T cell homing and elimi-
nating the development of a Th1 cell phenotype. These
experiments show a clear separation between the cellular
programs that promote cell division and those that result in
effector function and T cell memory. Furthermore, they il-
lustrate one functional consequence of the inherent flexi-
Figure 6. Antagonized 3.L2 T cells have activated caspase-3. Lymph
nodes and spleens from day 5 transfer recipients were analyzed by intra-
cellular staining for activated caspase-3. The data was gated on CD4 
CAb  cells (solid line) and the positive peak was established with an iso-
type-matched control antibody (dashed line). The percent of gated cells
with activated caspase-3 is indicated.Haribhai et al. 1379
bility (40–42) in TCR–ligand interaction. The capability of
T cells to simultaneously engage more than one peptide–
MHC complex, in this case an endogenous antagonist and
the cognate antigen, results in qualitative differences in
TCR activation and modified developmental programs.
These data demonstrate a role for the quality of TCR sig-
naling in determining cell fate and the potency of endoge-
nous peptide–MHC complexes in shaping the peripheral T
cell repertoire.
In the progressive differentiation model for CD4  and
CD8  T cells, the sequential acquisition of discrete func-
tional capacities by each clone activated in a primary re-
sponse depends upon the duration of TCR and cytokine
stimulation (2, 3, 6). Therefore, outcome hinges upon the
affinity of each TCR for antigen (11) and the ability of
each clone to compete for activated APCs and cytokines
(18). Less fit cells receiving insufficient stimulation will die
by neglect, whereas cells receiving sufficient stimulation
will sequentially become nonpolarized intermediates and
polarized effectors. Those cells receiving excessive stimula-
tion will die by activation-induced cell death. Memory
cells are postulated to develop from both nonpolarized in-
termediates and effectors, and some intermediates may me-
diate specialized functions such as B cell help or suppression
(1). In our system, the use of CFA and adequate doses of
peptide assures that all 3.L2 T cells receive a strong activa-
tion signal from mature dendritic cells. However, the pres-
ence of the antagonist redirects this signal, and the result in
vivo is a full proliferative response followed by altered
homing, anergy, and elimination of the expanded clone.
No 3.L2 T cell memory was observed, further demonstrat-
ing that nonpolarized intermediates or effector cells were
not generated. We conclude that cell division is the first
functional capacity to be acquired and that reaching this ac-
tivation threshold does not automatically result in the de-
velopment of effector function. Also, cell division in the
absence of effector differentiation results in clonal elimina-
tion rather than clonal contraction, as no 3.L2 T cells re-
Figure 7. 3.L2 T cells fail to de-
velop a memory response. (A) The
fitness (survival) of 3.L2 T cells
was determined by FACS analy-
sis of draining lymph nodes and
spleens at several time points after
primary immunization. The data
is gated on CD4  cells, and the
percent of lymphocytes that are
CAb   is indicated. In the far
right panels, mice were reimmu-
nized with 20 nmol Hb(64–76)
peptide in IFA after 10 wk and
analyzed 5 d later. The data are
representative of three experi-
ments and show persistence of
3.L2 T cells in I72  controls, but
not mice that express the antago-
nist. (B) 10 wk after primary im-
munization, transfer recipients
were analyzed for expression of
the memory T cell marker
CD44. Data show the percent of
CAb  cells that are CD44hi and
CD44low, and are representative
of three experiments. (C) Trans-
fer recipients and controls were
immunized as described in Materi-
als  and Methods. After 10 wk,
CD4   lymph node and spleen
cells were purified from pooled
samples and equal numbers of
CD4  cells were stimulated in a
lymph node proliferation assay
with fresh B6.AKR splenocytes
as APCs. The data show a recall
response in I72  transfer recipi-
ents ( ), but not in I72  mice
( ), where the minimal response
is less than that seen in I72  con-
trols without adoptive transfer of
3.L2 T cells ( ). I72   mice
without adoptive transfer ( )
have no recall response. The data
are the mean cpm incorporated
from three experiments.TCR Antagonists Promote Tolerance by Clonal Elimination 1380
main after 6–10 wk in mice that express the antagonist.
Thus, there is a clear separation between the instructional
program of clonal expansion and those programs that result
in effector function and T cell memory. This finding was
not predicted by the many in vitro studies describing the
effects of antagonist ligands, and it highlights the hierarchi-
cal, compartmental nature of an intact immune response.
Abortive proliferation as a mechanism of peripheral tol-
erance is also seen when immature dendritic cells cross-
present self-antigen to CD8  T cells (16). The deletion of
these autoreactive T cells was inhibited by Bcl-2 overex-
pression and also blocked in Bim-deficient T cells, suggest-
ing lack of a survival signal (43). Thus, low levels of T cell
stimulation by immature dendritic cells might be sufficient
for proliferation, but not survival or effector differentiation.
In our experiments, we observe a similar phenotype, sug-
gesting that antagonist-induced alterations in TCR signal-
ing might be qualitatively similar to those mediated by im-
mature dendritic cells.
The mechanism by which antagonists alter T cell activa-
tion is controversial. Affinity measurements between TCR
and peptide–MHC class II complexes using surface plas-
mon resonance have shown that antagonist peptides have
faster off rates than agonist peptides, leading to a reduced
half-life (11, 44). When viewed in the context of the ki-
netic proofreading model, these data suggest that antagonist
inhibition of T cell activation is due to a failure to fully in-
duce the T cell signaling cascade. This model is supported
by data demonstrating that antagonists elicit limited phos-
phorylation of the CD3-associated   chains (29, 45–47).
Both the total amount of   phosphorylation and the ratio of
the p23 to p21 kD isoforms are reduced by antagonist stim-
ulation, possibly resulting in an inhibitory signal. In con-
trast, studies using mutant   chain hybridomas or transgenic
mice have demonstrated that antagonism does not depend
upon differential phosphorylation of either the p21 or the
p23   isoforms, suggesting that altered   phosphorylation is
a consequence of antagonism (48, 49). In agreement with
these later observations, antagonists rapidly recruit SHP-1
to the TCR signaling complex (34), and transfected domi-
nant negative SHP-1 prevents antagonism (30). Lower af-
finity antagonist ligands trigger a negative feedback loop
mediated by SHP-1 dephosphorylation of Lck. Stimulatory
ligands activate a positive feedback mechanism that results
in phosphorylation of Lck by Erk, thereby blocking SHP-
1–Lck interactions (31). One caveat is that many studies in-
volve an analysis of TCR signals induced by either agonist
or antagonist ligands independently and in vitro. They do
not examine T cell activation when both ligands are
present together on an activated APC, as is the case in our
experiments and is arguably the more physiologically rele-
vant condition.
This body of evidence documents the relationship be-
tween ligand quality and the association of SHP-1 with the
TCR signaling complex. When viewed in this context,
one prediction based on our data is that upon transfer of
3.L2 T cells into I72 mice, SHP-1 would be rapidly re-
cruited to the TCR signaling complex, resulting in a nega-
tive effect on subsequent T cell activation. This association
is likely to require the continual presence of the antagonist
ligand. The capacity of 3.L2 T cells purified from I72 
transfer recipients to be stimulated normally supports the
transient, reversible nature of the antagonist effect and sug-
gests that the full biological potential of TCR antagonism is
only appreciated in the setting of inflammation.
It is important to point out that when the antagonist I72
is expressed in the thymus of 3.L2 mice, the result is the
elimination of those cells with high levels of the transgenic
TCR (37). In this adoptive transfer study, we circumvent
thymic processes to focus on the peripheral effect of this
class of self-ligand. This approach is warranted when one
considers that not all self-proteins are expressed in the thy-
mus. Furthermore, agonist ligands in low doses have been
shown to promote positive selection (50–52) and differen-
tiation into lineages with innate characteristics (53), sug-
gesting that negative selection is not the only functional
outcome of strong TCR–ligand interaction in the thymus.
In the later example, the developing thymocytes are repro-
grammed into a CD8   lineage, demonstrating a divergent
developmental pathway triggered by strong TCR–ligand
interactions (53).
As a group, endogenous MHC ligands are important in
T cell activation and contribute to T cell responses. They
heighten sensitivity to foreign antigens (33) and augment
clonal expansion after activation (54). During an immune
response, the number of MHC complexes displaying a for-
eign peptide is small and endogenous peptide–MHC com-
plexes contribute to synapse formation (19). This contribu-
tion to the total binding energy needed for stable synapse
formation can be substantial, regardless of the peptide(s)
bound by MHC molecules. For example, alanine scanning
mutagenesis of the MHC class I–restricted 2C TCR, com-
bined with binding data and structural analysis, revealed
that more than half of the binding energy for the 2C–QL9-
Ld complex can be assigned to 2C-Ld contacts (55). Taken
together, these observations demonstrate that TCR–MHC
contacts contribute to T cell signaling, even in the absence
of TCR–peptide interactions.
Antagonists appear to represent a class of endogenous
ligand with negative effects on peripheral T cell responses.
In our system, the 3.L2–I72-I-Ek complexes have a half-life
of 2–3 s,  25% of that seen for N72, the strongest stimula-
tory ligand (11). Based on binding energy alone, I72 would
be predicted to enhance 3.L2 T cell activation. Our data
demonstrate that this is not the case and support the hy-
pothesis that antagonists alter T cell signal transduction, re-
sulting in clonal elimination and T cell tolerance. There-
fore, antagonists are a ubiquitous class of self-ligand that
may have a significant effect on the shape of the peripheral
T cell repertoire by eliminating clones with self-reactive
TCRs that are activated during an immune response.
We thank Paul Allen for advice, the gift of the 3.L2 mice, and re-
view of the manuscript; Jack Gorski, Bonnie Dittel, Dave Eckels,
Manoj Mishra, Merav Lidar, and Carol Julin for review of the
manuscript; and Jennifer Ziegelbauer for assistance with the mice.Haribhai et al. 1381
This study was funded by Grants from the National Institutes of
Health, March of Dimes, and the Children’s Hospital of Wisconsin.
The authors have no conflicting financial interests.
Submitted: 21 June 2004
Accepted: 11 October 2004
References
1. Lanzavecchia, A., and F. Sallusto. 2000. Dynamics of T lym-
phocyte responses: intermediates, effectors, and memory cells.
Science. 290:92–97.
2. van Stipdonk, M.J., G. Hardenberg, M.S. Bijker, E.E. Lem-
mens, N.M. Droin, D.R. Green, and S.P. Schoenberger.
2003. Dynamic programming of CD8  T lymphocyte re-
sponses. Nat. Immunol. 4:361–365.
3. Gett, A.V., F. Sallusto, A. Lanzavecchia, and J. Geginat.
2003. T cell fitness determined by signal strength. Nat. Immu-
nol. 4:355–360.
4. Kaech, S.M., and R. Ahmed. 2001. Memory CD8  T cell
differentiation: initial antigen encounter triggers a develop-
mental program in naive cells. Nat. Immunol. 2:415–422.
5. Kaech, S.M., E.J. Wherry, and R. Ahmed. 2002. Effector
and memory T-cell differentiation: implications for vaccine
development. Nat. Rev. Immunol. 2:251–262.
6. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The
duration of antigenic stimulation determines the fate of naive
and effector T cells. Immunity. 8:89–95.
7. Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M.
Rivera, J.V. Ravetch, R.M. Steinman, and M.C. Nussen-
zweig. 2001. Dendritic cells induce peripheral T cell unre-
sponsiveness under steady state conditions in vivo. J. Exp.
Med. 194:769–779.
8. Masopust, D., S.M. Kaech, and R. Ahmed. 2004. The role
of programming in memory T-cell development. Curr. Opin.
Immunol. 16:217–225.
9. Reinhardt, R.L., A. Khoruts, R. Merica, T. Zell, and M.K.
Jenkins. 2001. Visualizing the generation of memory CD4 T
cells in the whole body. Nature. 410:101–105.
10. Alam, S.M., G.M. Davies, C.M. Lin, T. Zal, W. Nasholds,
S.C. Jameson, K.A. Hogquist, N.R. Gascoigne, and P.J.
Travers. 1999. Qualitative and quantitative differences in T
cell receptor binding of agonist and antagonist ligands. Immu-
nity. 10:227–237.
11. Kersh, G.J., E.N. Kersh, D.H. Fremont, and P.M. Allen.
1998. High- and low-potency ligands with similar affinities
for the TCR: the importance of kinetics in TCR signaling.
Immunity. 9:817–826.
12. Andres, P.G., K.C. Howland, A. Nirula, L.P. Kane, L. Bar-
ron, D. Dresnek, A. Sadra, J. Imboden, A. Weiss, and A.K.
Abbas. 2004. Distinct regions in the CD28 cytoplasmic do-
main are required for T helper type 2 differentiation. Nat.
Immunol. 5:435–442.
13. Song, J., S. Salek-Ardakani, P.R. Rogers, M. Cheng, L. Van
Parijs, and M. Croft. 2004. The costimulation-regulated du-
ration of PKB activation controls T cell longevity. Nat. Im-
munol. 5:150–158.
14. Singh, N.J., and R.H. Schwartz. 2003. The strength of per-
sistent antigenic stimulation modulates adaptive tolerance in
peripheral CD4  T cells. J. Exp. Med. 198:1107–1117.
15. Smith, K., B. Seddon, M.A. Purbhoo, R. Zamoyska, A.G.
Fisher, and M. Merkenschlager. 2001. Sensory adaptation in
naive peripheral CD4 T cells. J. Exp. Med. 194:1253–1261.
16. Kurts, C., H. Kosaka, F.R. Carbone, J.F. Miller, and W.R.
Heath. 1997. Class I–restricted cross-presentation of exoge-
nous self-antigens leads to deletion of autoreactive CD8  T
cells. J. Exp. Med. 186:239–245.
17. Itano, A.A., and M.K. Jenkins. 2003. Antigen presentation to
naive CD4 T cells in the lymph node. Nat. Immunol. 4:733–739.
18. Kedl, R.M., B.C. Schaefer, J.W. Kappler, and P. Marrack.
2002. T cells down-modulate peptide-MHC complexes on
APCs in vivo. Nat. Immunol. 3:27–32.
19. Wulfing, C., C. Sumen, M.D. Sjaastad, L.C. Wu, M.L. Dus-
tin, and M.M. Davis. 2002. Costimulation and endogenous
MHC ligands contribute to T cell recognition. Nat. Immunol.
3:42–47.
20. Huppa, J.B., M. Gleimer, C. Sumen, and M.M. Davis. 2003.
Continuous T cell receptor signaling required for synapse main-
tenance and full effector potential. Nat. Immunol. 4:749–755.
21. Alexander, J., K. Snoke, J. Ruppert, J. Sidney, M. Wall, S.
Southwood, C. Oseroff, T. Arrhenius, F.C. Gaeta, S.M. Co-
lon, et al. 1993. Functional consequences of engagement of the
T cell receptor by low affinity ligands. J. Immunol. 150:1–7.
22. De Magistris, M.T., J. Alexander, M. Coggeshall, A. Altman,
F.C. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analog-
major histocompatibility complexes act as antagonists of the
T cell receptor. Cell. 68:625–634.
23. Dittel, B.N., D.B. Sant’Angelo, and C.A. Janeway Jr. 1997.
Peptide antagonists inhibit proliferation and the production
of IL-4 and/or IFN-gamma in T helper 1, T helper 2, and T
helper 0 clones bearing the same TCR. J. Immunol. 158:
4065–4073.
24. Grakoui, A., S.K. Bromley, C. Sumen, M.M. Davis, A.S.
Shaw, P.M. Allen, and M.L. Dustin. 1999. The immunolog-
ical synapse: a molecular machine controlling T cell activa-
tion. Science. 285:221–227.
25. Zal, T., M.A. Zal, and N.R. Gascoigne. 2002. Inhibition of
T cell receptor-coreceptor interactions by antagonist ligands
visualized by live FRET imaging of the T-hybridoma immu-
nological synapse. Immunity. 16:521–534.
26. Plebanski, M., E.A. Lee, C.M. Hannan, K.L. Flanagan, S.C.
Gilbert, M.B. Gravenor, and A.V. Hill. 1999. Altered peptide
ligands narrow the repertoire of cellular immune responses by
interfering with T-cell priming. Nat. Med. 5:565–571.
27. Wang, J.H., T.J. Layden, and D.D. Eckels. 2003. Modulation
of the peripheral T-cell response by CD4 mutants of hepatitis
C virus: transition from a Th1 to a Th2 response. Hum. Im-
munol. 64:662–673.
28. Dittel, B.N. 2001. Mechanisms of T cell receptor antago-
nism: implications in the treatment of disease. Curr. Mol.
Med. 1:339–355.
29. Kersh, E.N., G.J. Kersh, and P.M. Allen. 1999. Partially
phosphorylated T cell receptor   molecules can inhibit T cell
activation. J. Exp. Med. 190:1627–1636.
30. Kilgore, N.E., J.D. Carter, U. Lorenz, and B.D. Evavold.
2003. Cutting edge: dependence of TCR antagonism on Src
homology 2 domain-containing protein tyrosine phosphatase
activity. J. Immunol. 170:4891–4895.
31. Stefanova, I., B. Hemmer, M. Vergelli, R. Martin, W.E.
Biddison, and R.N. Germain. 2003. TCR ligand discrimina-
tion is enforced by competing ERK positive and SHP-1 neg-
ative feedback pathways. Nat. Immunol. 4:248–254.
32. Basu, D., C.B. Williams, and P.M. Allen. 1998. In vivo an-
tagonism of a T cell response by an endogenously expressed
ligand. Proc. Natl. Acad. Sci. USA. 95:14332–14336.
33. Stefanova, I., J.R. Dorfman, and R.N. Germain. 2002. Self-TCR Antagonists Promote Tolerance by Clonal Elimination 1382
recognition promotes the foreign antigen sensitivity of naive
T lymphocytes. Nature. 420:429–434.
34. Dittel, B.N., I. Stefanova, R.N. Germain, and C.A. Janeway
Jr. 1999. Cross-antagonism of a T cell clone expressing two
distinct T cell receptors. Immunity. 11:289–298.
35. Robertson, J.M., and B.D. Evavold. 1999. Cutting edge: du-
eling TCRs: peptide antagonism of CD4  T cells with dual
antigen specificities. J. Immunol. 163:1750–1754.
36. Kersh, G.J., D.L. Donermeyer, K.E. Frederick, J.M. White,
B.L. Hsu, and P.M. Allen. 1998. TCR transgenic mice in
which usage of transgenic  - and  -chains is highly dependent
on the level of selecting ligand. J. Immunol. 161:585–593.
37. Williams, C.B., D.L. Engle, G.J. Kersh, J.M. White, and
P.M. Allen. 1999. A kinetic threshold between positive and
negative selection based on the longevity of the T cell recep-
tor-ligand complex. J. Exp. Med. 189:1531–1544.
38. Kersh, G.J., and P.M. Allen. 1996. Structural basis for T cell
recognition of altered peptide ligands: a single T cell receptor
can productively recognize a large continuum of related
ligands. J. Exp. Med. 184:1259–1268.
39. Williams, C.B., K. Vidal, D.L. Donermeyer, D.A. Peterson,
J.M. White, and P.M. Allen. 1998. In vivo expression of a T
cell receptor antagonist: T cells escape central tolerance but
are antagonized in the periphery. J. Immunol. 161:128–137.
40. Kersh, G.J., and P.M. Allen. 1996. Essential flexibility in the
T cell recognition of antigen. Nature. 222:495–498.
41. Reiser, J.B., C. Darnault, C. Gregoire, T. Mosser, G. Mazza,
A. Kearney, P.A. van der Merwe, J.C. Fontecilla-Camps, D.
Housset, and B. Malissen. 2003. CDR3 loop flexibility con-
tributes to the degeneracy of TCR recognition. Nat. Immu-
nol. 4:241–247.
42. Krogsgaard, M., N. Prado, E.J. Adams, X.L. He, D.C.
Chow, D.B. Wilson, K.C. Garcia, and M.M. Davis. 2003.
Evidence that structural rearrangements and/or flexibility
during TCR binding can contribute to T cell activation.
Mol. Cell. 12:1367–1378.
43. Davey, G.M., C. Kurts, J.F. Miller, P. Bouillet, A. Strasser,
A.G. Brooks, F.R. Carbone, and W.R. Heath. 2002. Periph-
eral deletion of autoreactive CD8 T cells by cross presenta-
tion of self-antigen occurs by a Bcl-2–inhibitable pathway
mediated by Bim. J. Exp. Med. 196:947–955.
44. Alam, S.M., P.J. Travers, J.L. Wung, W. Nasholds, S. Red-
path, S.C. Jameson, and N.R.J. Gascoigne. 1996. T cell re-
ceptor affinity and thymocyte positive selection. Nature. 381:
616–620.
45. Sloan-Lancaster, J., A.S. Shaw, J.B. Rothbard, and P.M.
Allen. 1994. Partial T cell signaling: altered phospho-zeta and
lack of zap70 recruitment in APL-induced T cell anergy.
Cell. 79:913–922.
46. Madrenas, J., R.L. Wange, J.L. Wang, N. Isakov, L.E.
Samelson, and R.N. Germain. 1995. Zeta phosphorylation
without ZAP-70 activation induced by TCR antagonists or
partial agonists. Science. 267:515–518.
47. Kersh, E.N., A.S. Shaw, and P.M. Allen. 1998. Fidelity of T
cell activation through multistep T cell receptor   phosphor-
ylation. Science. 281:572–575.
48. Liu, H., and D.A. Vignali. 1999. Differential CD3 zeta phos-
phorylation is not required for the induction of T cell antag-
onism by altered peptide ligands. J. Immunol. 163:599–602.
49. Pitcher, L.A., P.S. Ohashi, and N.S. van Oers. 2003. T cell
antagonism is functionally uncoupled from the 21- and 23-
kDa tyrosine-phosphorylated TCR zeta subunits. J. Immunol.
171:845–852.
50. Sebzda, E., V.A. Wallace, J. Mayer, R.S.M. Yeung, T.W.
Mak, and P.S. Ohashi. 1994. Positive and negative thy-
mocyte selection induced by different concentrations of a
single peptide. Science. 263:1615–1618.
51. Wang, R., A. Nelson, K. Kimachi, H.M. Grey, and A.G.
Farr. 1998. The role of peptides in thymic positive selection
of class II major histocompatibility complex-restricted T cells.
Proc. Natl. Acad. Sci. USA. 95:3804–3809.
52. Kraj, P., R. Pacholczyk, H. Ignatowicz, P. Kisielow, P.
Jensen, and L. Ignatowicz. 2001. Positive selection of CD4 
T cells is induced in vivo by agonist and inhibited by antago-
nist peptides. J. Exp. Med. 194:407–416.
53. Yamagata, T., D. Mathis, and C. Benoist. 2004. Self-reactiv-
ity in thymic double-positive cells commits cells to a CD8  
lineage with characteristics of innate immune cells. Nat. Im-
munol. 5:597–605.
54. Stefanova, I., J.R. Dorfman, M. Tsukamoto, and R.N. Ger-
main. 2003. On the role of self-recognition in T cell re-
sponses to foreign antigen. Immunol. Rev. 191:97–106.
55. Manning, T.C., C.J. Schlueter, T.C. Brodnicki, E.A. Parke,
J.A. Speir, K.C. Garcia, L. Teyton, I.A. Wilson, and D.M.
Kranz. 1998. Alanine scanning mutagenesis of an alphabeta T
cell receptor: mapping the energy of antigen recognition. Im-
munity. 8:413–425.